Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2005

01-10-2005

Assessment of the International Prognostic Scoring System for Determining Chemotherapeutic Indications in Myelodysplastic Syndrome: Japanese Retrospective Multicenter Study

Authors: Yoshikazu Ito, Kazuma Ohyashiki, Hisamaru Hirai, Seishi Ogawa, Kinuko Mitani, Tomomitsu Hotta, Masami Bessho, Tomoki Naoe, Hideaki Mizoguchi, Takashi Uchiyama, Mitsuhiro Omine

Published in: International Journal of Hematology | Issue 3/2005

Login to get access
Metadata
Title
Assessment of the International Prognostic Scoring System for Determining Chemotherapeutic Indications in Myelodysplastic Syndrome: Japanese Retrospective Multicenter Study
Authors
Yoshikazu Ito
Kazuma Ohyashiki
Hisamaru Hirai
Seishi Ogawa
Kinuko Mitani
Tomomitsu Hotta
Masami Bessho
Tomoki Naoe
Hideaki Mizoguchi
Takashi Uchiyama
Mitsuhiro Omine
Publication date
01-10-2005
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2005
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.04191

Other articles of this Issue 3/2005

International Journal of Hematology 3/2005 Go to the issue

Case Report

Cicatricial Pemphigoid of the Oropharynx after Allogeneic Stem Cell Transplantation for Relapsed Follicular Lymphoma

In memoriam susumu hibino, MD 1908–2005

A Tribute to the Memory of Susumu Hibino, MD

OriginalPaper

Dyskeratosis Congenita: A Disorder of Defective Telomere Maintenance?

OriginalPaper

Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission Therapies

OriginalPaper

Immune Pathophysiology of Aplastic Anemia

OriginalPaper

CD52 Is Not a Promising Immunotherapy Target for Most Patients with Multiple Myeloma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits